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Abstract  
Mephedrone (4-methyl-N-methylcathinone) is a psychostimulant that promotes release 
of monoamines via the high affinity transporters for dopamine (DAT), norepinephrine 
(NET) and serotonin (SERT). Metabolic breakdown of mephedrone results in bioactive 
metabolites that act as substrate-type releasers at monoamine transporters and 
stereospecific metabolism of mephedrone has been reported. This study compared the 
effects of the enantiomers of the phase-1 metabolites nor-mephedrone, 4-hydroxytolyl-
mephedrone (4-OH-mephedrone) and dihydro-mephedrone on (i) DAT, NET and SERT 
mediated substrate fluxes, (ii) determined their binding affinities towards a battery of 
monoamine receptors and (iii) examined the relative abundance of the enantiomers in 
human urine. 
Each of the enantiomers tested inhibited uptake mediated by DAT, NET and SERT. No 
marked differences were detected at DAT and NET. However, at SERT, the S-
enantiomers of nor-mephedrone and 4-OH-mephedrone were several times more 
potent than the corresponding R-enantiomers. Moreover, the R-enantiomers were 
ineffective as releasers at SERT. S-nor-mephedrone displayed moderate affinities 
towards human alpha1A, human 5-HT2A and rat and mouse trace amine-associated 
receptor 1.  
These results demonstrate that stereochemistry dictates the pharmacodynamics of the 
phase-1 metabolites of mephedrone at SERT, but not at DAT and NET, which manifests 
in marked differences in their relative potencies, i.e. DAT/SERT ratios. Chiral analysis of 
urine samples demonstrated that nor-mephedrone predominantly exists as the S-
enantiomer. Given the asymmetric abundance of the enantiomers in biological samples, 
these findings may add to our understanding of the subjective effects of administered 
mephedrone, which indicate pronounced effects on the serotonergic system. 
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1. Introduction  
Mephedrone is a methcathinone analogue with stimulant properties. Although 
mephedrone was synthesized in 1929, first reports on its abuse appeared in 2007 (Kelly, 
2011; Pedersen et al., 2013). Together with its congeners 3,4-
methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxymethcathinone 
(methylone), mephedrone belongs to a series of cathinones that received major 
attention from the media as so-called “bath salts” (Spiller et al., 2011), thus creating 
public awareness of new psychoactive substances (NPS) that are introduced into global 
drug markets (Brandt et al., 2014). NPS provide synthetic and easily accessible 
alternatives to well-established and scheduled drugs (Baumann and Volkow, 2016). 
Psychostimulant-type NPS generally fall into the classes of phenethylamines or 
cathinones (Tyrkko et al., 2016). Some NPS became established within drug markets and 
abuse continues despite their ban whereas others appear only locally and/or 
temporarily (World Drug Report 2016). Mephedrone was banned in most western 
countries in 2010 to 2011 (Green et al., 2014). However, converging lines of evidence 
indicate persistent abuse of this compound (Archer et al., 2013; Archer et al., 2014; 
Castiglioni et al., 2015; Salomone et al., 2016; Styszko et al., 2016), indicating that 
mephedrone became a widely accepted drug for recreational consumption in some 
regions (Hockenhull et al., 2016; Ordak et al., 2018).  
Pharmacologically, mephedrone exerts its effects by targeting the high-affinity 
monoamine transporters (MATs) for dopamine (DAT), norepinephrine (NET) and 
serotonin (5-HT, SERT), members of the solute carrier 6 family (Baumann et al., 2012; 
Eshleman et al., 2013; Hadlock et al., 2011; Martinez-Clemente et al., 2012; Simmler et 
al., 2013). DAT, NET and SERT retrieve monoamines from the extracellular space and 
terminate their activity at the pre- and postsynaptic receptors (Kristensen et al., 2011). 
Monoaminergic signalling is involved in various aspects of brain function, including 
motor function, motivation and reward. Thus, MATs are associated with a rich 
pharmacology and serve as molecular targets for clinically relevant (e.g. 
antidepressants) and recreationally ingested compounds (Sitte and Freissmuth, 2015; 
Torres et al., 2003). Generally, drugs that interfere with MAT-function are of two types: 
a) non-transported inhibitors, e.g. cocaine or antidepressants, which trap the 
transporter in a specific conformational state and arrest the transport cycle and b) 
substrate-type releasers. The latter are actively transported by MATs and promote 
reverse transport of cytosolic monoamines across the plasma membrane (Sitte and 
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Freissmuth, 2015). Mephedrone acts as a non-selective substrate-type releaser at DAT, 
NET and SERT (Baumann et al., 2012; Eshleman et al., 2013; Mayer et al., 2016; Pifl et al., 
2015; Simmler et al., 2013) and thus induces transporter-mediated release of 
monoamines. 
A variety of cathinones and phenethylamines contain a chiral carbon atom and exist as 
stereoisomers. Stereochemistry has a bearing on the neurochemistry and behavior 
associated with psychostimulants. For instance, racemic methcathinone was associated 
with neurotoxicity in dopaminergic neurons, whereas only S-methcathinone caused 
toxic effects on serotonergic neurons (Sparago et al., 1996). S-MDMA was found to be 
more potent than R-MDMA in inducing substrate-efflux at SERT (Rudnick and Wall, 
1992) and both enantiomers differed in their endocrine and neurochemical effects 
(Murnane et al., 2010). Stereospecific effects have also been reported for mephedrone, 
both in vitro and in vivo. The R- and S-enantiomers of mephedrone are equipotent as 
releasers at DAT and NET. At SERT, however, S-mephedrone is 40 times more potent 
than R-mephedrone (Gregg et al., 2015). In the same study, only R-mephedrone resulted 
in conditioned place preference and R-mephedrone produced greater intracranial self-
stimulation and sensitization to repetitive movements. In rats trained to self-administer 
the stereoisomers of mephedrone, R-mephedrone was associated with higher break 
points than S-mephedrone under progressive ratio access conditions (Philogene-Khalid 
et al., 2017b). 
In contrast to the prototypical stimulant amphetamine (“speed”), mephedrone exerts 
additional entactogenic effects and drug users report that the subjective effects 
resemble those of 3,4-methylendioxymethylamphetamine (MDMA, “ecstasy”) (Schifano 
et al., 2011). Simmler et al. (Simmler et al., 2013) concluded that the entactogenic effects 
of mephedrone arise from its ability to release serotonin in the brain in vivo to a greater 
extent when compared to dopamine (Baumann et al., 2012), resembling the effects of 
MDMA but contrasting those of amphetamine (Baumann et al., 2012; Kehr et al., 2011). 
Racemic mephedrone, however, does not favor SERT over DAT (Baumann, 2012, 
Eshleman, 2013, Hadlock, 2011). Enzymatic degradation of mephedrone gives rise to 
various phase-1 metabolites (Pedersen et al., 2013) (Figure 1). Our laboratory 
demonstrated that the phase-1 metabolites of mephedrone possess bioactive properties, 
thus might contribute to the actions of the parental compound. Systemic administration 
of the N-demethylated metabolite nor-mephedrone results in a profound increase in 
extracellular serotonin but has only blunted effects on extracellular dopamine in nucleus 
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accumbens (Mayer et al., 2016). Recently, stereospecific metabolism of mephedrone was 
reported (Castrignano et al., 2017). We therefore hypothesized that stereospecific 
pharmacokinetics and pharmacodynamics of the phase-1 metabolites may contribute to 
the overall effects of mephedrone. We performed in vitro assays to determine the effects 
of nor-mephedrone, 4-hydroxytolyl-mephedrone (4-OH-mephedrone) and dihydro-
mephedrone in their enantiopure form on monoamine transporters and receptors. We 
have also analyzed human urine samples for the abundance of the stereoisomers of nor-
mephedrone and 4-OH-mephedrone. 
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2. Methods (1948 words) 
 
2.1. Cell Culture 
Human embryonic 293 cells (HEK293 cells) were maintained at a subconfluent state in 
humidified atmosphere (37°C, 5% CO2) in Dulbecco’s Modified Eagle Medium (DMEM), 
containing 10 % heat-inactivated fetal calf serum (FCS), streptomycin (100 µg x 100 mL-
1) and penicillin (100 U x 100 mL-1). Geneticin (50 µg x mL-1) was added to select 
HEK293 cells stably expressing the human isoforms of DAT, NET and SERT as described 
in (Mayer et al., 2017). For uptake inhibition experiments cells expressing the desired 
transporter were seeded (40,000 cells per well in a final volume of 200 µL) onto poly-D-
lysine (PDL) coated 96-well plates 24 hours prior to the experiment. The same 
procedure was applied for release experiments, with the only modification that PDL-
coated glass-coverslips (diameter 5 mm) were placed into the 96-well plates (Mayer et 
al., 2017). 
 
Cells used for membrane preparations for the radioligand binding assays were cultured 
and prepared as described previously (Luethi et al., 2018b). The cells were harvested by 
adding trypsin/ethylenediaminetetraacetic acid (EDTA), washed with ice-cold PBS, 
pelleted by centrifugation (1000 rpm for 5 minutes at 4°C), and frozen and stored at -
80°C. The frozen pellets were then suspended in 20 mL (receptor binding) or 400 mL 
(transporter binding) HEPES-NaOH (20 mM, pH 7.4) containing 10 mM EDTA, and 
homogenized at 14,000 rpm for 20 seconds (receptor binding) or 10,000 rpm for 15 
seconds (transporter binding). The homogenates were then centrifuged at 48,000 g and 
4°C for 30 minutes and the supernatants were discarded. The pellets were then 
resuspended in 20 ml HEPES-NaOH (20 mM, pH 7.4) containing 0.1 mM EDTA and 
homogenized at 14,000 rpm for 20 seconds. Centrifugation and removal of the 
supernatant was repeated, before the final pellet was resuspended in HEPES-NaOH 
containing 0.1 mM EDTA and homogenized. The following transfected cell lines were 
used for the binding assays: HEK293 cells (5-HT1A, 5-HT2A, 5-HT2C, TAAR1, hDAT, hNET, 
and hSERT), Chinese hamster ovary (CHO) cells (α1A) and Chinese hamster lung (CHL) 
cells (α2A). 
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2.2. Uptake Inhibition Experiments 
For uptake inhibition assays, cell culture medium was replaced with Krebs-HEPES buffer 
(KHB: 25 mM HEPES, 120 mM NaCl, 5 mM KCl, 1.2 mM CaCl2, and 1.2 mM MgSO4 and 5 
mM D-glucose, pH adjusted to 7.3) (200 µL per well). Subsequently, the cells were 
incubated with increasing concentrations of the substance of interest. After 300 seconds, 
tritiated substrates (20 nM [3H]MPP+ for DAT and NET and 100 nM [3H]5-HT for SERT) 
were added. After 180 (DAT and NET) or 60 seconds (SERT), the tritiated substrates 
were removed and the cells were washed with ice-cold KHB (200 µL per well). Finally, 
the cells were lysed with 1% sodium dodecyl sulphate (SDS, 100 µL per well) and the 
amount of tritium within the cells was determined by use of a beta-scintillation counter. 
Nonspecific uptake was determined in the presence of 10 µM mazindol (DAT, NET) or 
10 µM paroxetine (SERT) and subtracted. Uptake in the absence of the substance of 
interest was defined as 100% uptake. The IC50 values were determined by non-linear 
regression fits (GraphPad Prism version 5.0; log(inhibitor) vs. response –variable slope 
four parameters (Y= Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)); fitting 
method: Least squares (ordinary) fit without weighting to minimize the absolute 
distances squared) as described in (Mayer et al., 2017).  
 
2.3. Release Experiments 
Dynamic superfusion experiments were performed as previously described (Mayer et 
al., 2017; Sitte et al., 2000). Briefly, SERT expressing HEK293 cells were grown on PDL-
coated glass coverslips and pre-loaded with [3H]5-HT by exposing the cells to 0.4 µM 
[3H]5-HT (in KHB) for 20 minutes at 37°C. Subsequently, the cells were placed in 
superfusion chambers with a volume of 200 µL and superfused with KHB at a flow rate 
of 0.7 mL per minute for 40 minutes to establish a stable baseline before the collection 
of 2 minute-fractions was started. After three basal fractions, the cells were superfused 
with KHB containing the substance of interest (0, 1, 3, 10, 30 and 100 µM) for five 
fractions. Finally, the cells were superfused with 1% SDS for three fractions to 
determine the total amount of radioactivity within the cells at the end of the experiment. 
The amount of tritium within the superfusates was determined with a beta-scintillation 
counter and the release of [3H]5-HT was expressed as a fractional rate, i.e. the 
radioactivity present within each fraction was expressed as the percentage of the total 
radioactivity present at the beginning of that fraction (Sitte et al., 2000). 
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The superfusion apparatus has 12 individual chambers. Hence, each independent 
observation allowed for the monitoring of six different concentrations (each in 
duplicate). To monitor inter-experimental consistency, randomly selected 
concentrations were included in following experiments, giving rise to individual 
differences in sample sizes in Figure 3 and 4. 
 
2.4. Receptor and Transporter Binding and Activation Assays 
Radioligand binding assays were performed as described in detail for each receptor and 
transporter in (Luethi et al., 2018b). The membrane preparations that overexpressed the 
respective receptors or transporters (human genes, with the exception of rat and mouse genes 
for TAAR1) were incubated with radiolabelled ligands and ligand displacement by the 
compounds was measured. The difference between total binding (binding buffer alone) and 
nonspecific binding (in the presence of specific competitors) was determined to be specific 
binding. The radioligands and competitors are listed in Table 1.  
IC50 values were derived from three concentration-effect curves using 10 different 
concentrations. The validity of this measurement is dependent on the amount of single data 
points (concentration-effect measurements) and the appropriate selection of sufficient points 
within the slope of the curve (>5 for each experiment). Thus, the amount and level of 
concentrations tested defines accurate IC50 values rather than the number of experiments (with 
potentially fewer concentrations or concentrations not within the slope). GraphPad was used 
to derive each IC50 value from the modeled curves using in total 30 data points by logistic 
regression. The Cheng-Prusoff equation was used to calculate Ki values. No observed affinity 
within a concentration range indicates that there was no binding at the highest tested 
concentration as well as no binding at 9 different lower concentrations. 
 
Receptor/ 
Transporter 
hTAAR1 rTAAR1  mTAAR1 h5-HT1A h5-HT2A h5-HT2C 
Radioligand [3H]RO5166
017 
[3H]RO516601
7 
[3H]-8-OH-
DPAT 
[3H]Ketanseri
n 
FLIPR assay [3H] 
Mesulergine 
Non-
specific 
binding 
10 µM 
RO5166017 
10 µM 
RO5166017 
10 µM 
pindolol 
10 µM 
spiperone 
FLIPR assay 10 µM 
mianserin 
       
Receptor/ 
Transporter 
hα1A hα2A hDAT hNET hSERT  
 10
Radioligand [3H]Prazosin [3H]Rauwolsci
ne 
[3H]WIN35,42
8 
N-methyl-
[3H]Nisoxeti
ne 
[3H]Citalopr
am 
 
Non-
specific 
binding 
10 µM  
chlor-
promazine 
10 µM phentol-
amine 
10 µM 
indatraline 
10 µM 
indatraline 
10 µM 
indatraline 
 
Table 1: Radioligands and non-specific binding determinants used in receptor and transporter 
binding assays.  
 
The activation potential at the serotonin 5-HT2B receptor was assessed as described in (Luethi 
et al., 2018b). HEK293 cells expressing the human 5-HT2B receptor were incubated in PDL-
coated 96-well plates overnight. Thereafter, the growth medium was removed by snap 
inversion, 100 µl of calcium indicator Fluo-4 solution (Molecular Probes, Eugene, OR, USA) 
was added to each well and the plates were incubated for 45 minutes at 31°C. The Fluo-4 
solution was then removed by snap inversion before 100 µL of Fluo-4 solution was added 
again for 45 minutes at 31°C. After washing the cells, 100 µL assay buffer was added. 
Finally, the plates were placed in a fluorescence imaging plate reader (FLIPR), 25 µL of the 
test drugs diluted in assay buffer was added online and the increase in fluorescence was 
measured. EC50 values were derived from concentration-response curves using nonlinear 
regression. 
The activation potential at the human TAAR1 was assessed as described in (Luethi et al., 
2018b). Recombinant HEK 293 cells expressing the human TAAR1 were harvested and 
pelleted by centrifugation at 900 rpm for 3 minutes at room temperature. The supernatant was 
removed and the cell pellet was resuspended in fresh culture medium. The cells were then 
plated into 96-well plates (100 µl per well, 80,000 cells per well) and incubated for 20 hours 
at 37°C. For the cAMP assay, the cell culture medium was removed, and 50 µl of PBS 
(without Ca2+ and Mg2+) was added. Thereafter, PBS was removed by snap inversion and 90 
µl of Krebs-Ringer bicarbonate buffer containing 1 mM IBMX was added. The plates were 
then incubated for 60 minutes at 37°C. All compounds were tested at a broad range of 
concentrations (300 pM – 30 µM) in duplicate and a standard curve (0.13 nM – 10 µM 
cAMP) was included on each plate. Additionally, a reference plate containing RO5256390, β-
phenylethylamine and p-tyramine was included in each experiment. Typically, 30 µl of a 
compound solution, 30 µl of β-phenylethylamine (as maximal response) or a basal control 
was added, and the cells were incubated for 40 minutes at 37°C. Finally, the cells were lysed 
with 50 µl of detection mix solution containing Ru-cAMP Alexa700 anti-cAMP antibody and 
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lysis buffer for 120 minutes at room temperature under heavy shaking. Fluorescence was 
measured using a NanoScan (IOM reader; 456 nm excitation wavelength; 630 and 700 nm 
emission wavelengths). The FRET signal was calculated as the following: FRET (700 nM) – 
P × FRET (630 nM), where P = Ru (700 nM) / Ru (630 nM). 
Receptor and transporter affinity data of a variety of previously published psychedelics and 
stimulants (Luethi et al., 2018a; Luethi et al., 2018b) verified that the material used was fully 
binding competent.  
 
2.5. Enantiomeric profiling of nor- and 4-OH-mephedrone in human urine samples 
After written consent, the urine sample was provided by the Vienna Police Department. 
The anonymized sample used in the present study tested positive for mephedrone and 
was obtained during roadside testing of drivers under the influence of drugs in the 
Vienna area. Prior to analysis of a human urine sample, an HPLC gradient was optimized 
for the chiral separation of nor-mephedrone and 4-OH-mephedrone. Since direct chiral 
chromatographic separation of enantiomeric pairs with mass spectrometry (MS) under 
compatible conditions was not successful, we employed a chiral derivatization protocol 
described previously (Mohr et al., 2012) to obtain the corresponding diastereoisomers 
in order to facilitate chromatographic separation. The single enantiomers of nor-
mephedrone and 4-OH-mephedrone were treated with S-(-)-N-
(trifluoroacetyl)pyrrolidine-2-carbonyl chloride (L-TPC) under basic conditions, thus 
yielding their corresponding diastereoisomeric amides. Under these conditions it is 
possible that partial racemization of the substrates may occur. We found that the 
racemization in the  case of nor-mephedrone was negligible (approximately 1%), 
whereas in the case of 4-OH-mephedrone the S- enantiomer tended to slightly (12%) 
racemize towards the R-enantiomer (still enabling unequivocal assignment of 
stereochemistry when utilizing optically pure material). It is noteworthy, that partial 
racemization was also observed for free-base representatives of this compound series 
under physiological conditions. Hence, pure isomers were generally employed as 
hydrochloride salts displaying significantly higher stability of optical purity. 
First, the MS behaviour of derivatized metabolites as reference standards was studied in 
order to find characteristic ionization and fragmentation patterns. Detection and 
identification of derivatized metabolites were accomplished by analysis by LC-MS/MS of 
directly diluted biological specimens. The urine sample was subjected to the 
derivatization protocol without prior glucuronidase and arylsulphatase work-up since 
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4-OH-mephedrone was found to decompose completely during this process. 
Metamfepramone was chosen as the internal standard due to its availability and 
structural similarity to the metabolites and due to the fact that it cannot be modified via 
derivatization conditions. Any urinary matrix effect on the calibration curve was 
evaluated by analyzing the standards spiked into human urine. 
 
2.6. Data Acquisition and Analysis  
Blinding: a code (three letters, three digits; e.g. LAU644 for S-4-OH-mephedrone) was 
assigned to the individual stereoisomers of the phase-1 metabolites. Experiments were 
performed with the identity of the metabolites being masked to the experimenter. 
Calculations were performed with Micosoft Excel 2010 (Microsoft Corporation, 
Redmond, WA, USA). Analysis was performed with GraphPad 5.0 (GraphPad Software 
Inc., La Jolla, CA, USA). Efflux data were analyzed by two-way ANOVA (treatment x time) 
followed by Bonferroni’s test. P values <0.05 were considered significant.  
 
2.7. Materials 
The phase-1 metabolites were synthesized in their enantiopure form. Detailed 
descriptions of the synthetic procedures and the chemical characterizations are given in 
the Supporting Information. [3H]MPP+ (80-85 µCi mmol-1) was purchased from 
American Radiolabled Chemicals (St. Louis, MO, USA) and [3H]5-HT (28.3 µCI mmol-1), 
[3H]8-OH-DPAT, [3H]ketanserin, [3H]mesulergine, [3H]prazosin, [3H]rauwolscine, N-
methyl-[3H]nisoxetine, [3H]WIN35,428 and [3H]citalopram were purchased from Perkin 
Elmer (Boston, MA, USA). [3H]RO5166017 and RO5166017 were provided by F. 
Hoffmann-La Roche (Basel, Switzerland). All other chemicals were from Sigma-Aldrich 
(St. Louis, MO, USA). 
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3. Results (643 words) 
 
3.1. The stereoisomers of phase-1 metabolites inhibit transporter-mediated uptake  
To test whether each stereoisomer of the metabolites interacts with MATs, we 
performed uptake inhibition experiments. The stereoisomers of nor-, 4-OH and dihydro-
mephedrone were fully efficacious inhibitors of DAT, NET and SERT mediated uptake 
(Figure 2). The stereoisomers of nor-mephedrone inhibited DAT and NET with 
comparable potencies in the low micromolar range, with IC50 values ranging from 
approximately 3 to 10 µM. At SERT, R-nor-mephedrone was 18 times less potent than S-
nor-mephedrone, with corresponding IC50 values of 200.0 and 10.9 µM, respectively. 
The IC50 values of S- and R-4-OH-mephedrone to inhibit DAT-mediated uptake were 
within the same level of potency, i.e. 2.63 and 5.64 µM, respectively. For NET, the IC50 
values were 9.53 and 18.04 µM for S- and R-4-OH-mephedrone, respectively. At SERT, S-
4-OH-mephedrone (IC50 32.1 µM) was a 19 times more potent inhibitor than R-4-OH-
mephedrone (IC50 625.4 µM). The four stereoisomers of dihydro-mephedrone displayed 
varying potencies as inhibitors at each MAT, with IC50 values spanning concentrations 
from 12 to 216 µM. The IC50 values and the corresponding NET/DAT and DAT/SERT 
ratios are summarized in Table 2. 
 
3.2. The stereoisomers of nor- and 4-OH-mephedrone differentially affect SERT-mediated 
reverse transport 
Nor-, 4-OH- and dihydro-mephedrone act as transportable substrates of MATs (Mayer et 
al., 2016). We performed release experiments to investigate whether the observed 
differences between the R- and S-enantiomers of nor- and 4-OH-mephedrone on SERT-
mediated uptake also apply to reverse transport. HEK293 cells stably expressing hSERT 
were pre-loaded with [3H]5-HT and superfused with buffer containing increasing 
concentrations of test drugs.  
Application of two-way ANOVA (concentration x time) demonstrated that S- (F5. 51 = 
26.71; P < 0.0001) and R-nor-mephedrone (F5.38 = 6.14; P = 0.0003) significantly affected 
the release of tritiated substrate (Figures 3A and C). Post hoc tests revealed that 3, 10, 30 
and 100 µM of S-nor-mephedrone significantly elevated reverse transport via SERT 
versus the vehicle control. For R-nor-mephedrone, significant effects were observed at 
30 and 100 µM. Concentrations of S-nor-mephedrone exceeding 10 µM did not stimulate 
the release of tritiated 5-HT to a further extent but rather exhibited a trend back 
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towards baseline (Figure 3B). This finding is in agreement with earlier observations, 
demonstrating a biphasic effect of substrate type-releasers on SERT mediated reverse 
transport (Seidel et al., 2005). S-4-OH-mephedrone significantly affected outwardly-
directed transport of [3H]5-HT (F5.63 = 44.74; P < 0.0001) (Figure 4A). Post hoc analysis 
demonstrated significant differences at concentrations of 10 µM or higher. No main 
effect was detected for R-4-OH-mephedrone (F5.51 = 0.69; P = 0.63) ( Figure 4B). Neither 
R-nor-mephedrone nor S-4-OH-mephedrone gave rise to bell-shaped concentration 
response curves (Figures 4C and D); this may indicate that the applied concentrations 
are non-saturating in our experimental system (Seidel et al., 2005). 
 
3.3. Monoamine receptor and transporter binding profiles  
Monoamine receptor binding profiles are summarized in Table 3 and Table 4. None of 
the tested metabolites bound to 5-HT1A or 5-HT2C receptors, nor did they activate the 5-
HT2B receptor. S-nor-mephedrone exhibited submicromolar affinities towards rat and 
mouse TAAR1 (Ki = 0.58 and 0.72 µM, respectively) and supramicromolar affinities 
towards human 5-HT2A (Ki = 7.41 µM) and α1A (Ki = 1.33 µM) receptors. 1R,2R-, 1S,2S- 
and 1R,2S-dihydro-mephedrone bound to rat TAAR1 (Ki = 3.71, 3.57 and 0.56 µM, 
respectively), but only 1S,2S-dihydro-mephedrone interacted with mouse TAAR1 (Ki = 
3.85 µM). However, no human TAAR1 activity was observed in the concentration range 
investigated (EC50 > 30 µM). 1S,2S- and 1R,2S-dihydro-mephedrone interacted with 5-
HT2A receptors (Ki = 6.66 and 7.47 µM, respectively), whereas only 1R,2S-dihydro-
mephedrone had affinity to the α2A receptor (Ki = 1.85 µM). None of the test drugs bound 
to MATs with submicromolar affinities. 
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4. Discussion  
The intention of the present study was to investigate the effects of selected phase-1 
metabolites of mephedrone in their enantiopure form on monoamine receptors and 
transporters. Stereospecific pharmacology has been reported for various compounds 
that target MATs, including cathinone (Hutsell et al., 2016), methcathinone (Sparago et 
al., 1996), amphetamine (Sitte et al., 1998), MDMA (Rudnick and Wall, 1992) and 
mephedrone (Gregg et al., 2015; Philogene-Khalid et al., 2017a; Philogene-Khalid et al., 
2017b; Vouga et al., 2015). In this study, we found that the stereochemistry affects the 
pharmacology of the phase-1 metabolites of mephedrone. Each of the stereoisomers 
tested inhibited MAT-mediated uptake in a concentration dependent manner. In the 
case of nor-mephedrone, both enantiomers inhibited DAT and NET with comparable 
potencies. At SERT, however, S-nor-mephedrone revealed a pronounced leftward-shift 
when compared to the R-stereoisomer. This observation is consistent with a recent 
publication (Hutsell et al., 2016), demonstrating that the R-enantiomer of nor-
mephedrone is less potent than S-nor-mephedrone at SERT. Uptake inhibition assays 
with 4-OH-mephedrone revealed a potency loss from the S- to the R-enantiomer at all 
three MATs. Remarkably, this rightward-shift was again more pronounced at SERT 
(~19-fold) than at DAT and NET (~2-fold). The four stereoisomers of dihydro-
mephedrone were associated with a more complex pharmacology. The differences in 
potency were again more pronounced at SERT (up to 10-fold) than at DAT and NET (~2-
fold).  
A recent study revealed that mephedrone undergoes stereospecific metabolism and the 
stereoisomers of nor- and 4-OH-mephedrone were detected in biological samples 
(Castrignano et al., 2017). Based on the differing potencies as inhibitors of SERT-
mediated uptake, we sought to perform release experiments with the stereoisomers of 
nor- and 4-OH-mephedrone in SERT-expressing HEK293 cells. Remarkably, only the S-
enantiomers of nor- and 4-OH-mephedrone acted as fully-fledged releasers at SERT. In 
the case of R-nor-mephedrone, blunted effects on SERT-mediated reverse transport 
were observed at 100 µM. R-4-OH-mephedrone failed to cause significant effects over 
the entire range of concentrations tested (1 to 100 µM). It is unlikely that this effect is 
solely attributable to the reduced potencies as uptake inhibitors: the IC50 of R-nor-
mephedrone to inhibit SERT-mediated uptake (200 µM, which – following the Cheng-
Prusoff equation – reflects its Ki-value) is only two times higher than the highest 
concentration applied in release-experiments. Hence, it can be assumed that a 
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considerable proportion of transporters will be occupied by R-nor-mephedrone at this 
concentration. According to Seidel and colleagues (Seidel et al., 2005), the maximal 
effect on reverse-transport elicited by amphetamine-like drugs is expected to occur at 
concentrations around the corresponding Ki-value of the tested drug. This explanation 
may not apply to R-4-OH-mephedrone (IC50 ~625 µM). However, due to limited drug 
availability, we did not test concentrations higher than 100 µM. We do not feel that 
increasing the concentration is necessary, as non-specific, i.e. non-SERT-related, effects 
may superimpose transporter-mediated tracer fluxes. Furthermore, considering the 
recreational doses of mephedrone (up to 90 mg nasally and 250 mg orally (Schifano et 
al., 2011)), it is more than unlikely that R-4-OH-mephedrone builds up at concentrations 
beyond the ones applied in our experiments. One possible explanation for the observed 
effects is that the three-dimensional difference between S- and R-enantiomers affects 
their interaction with the binding pocket, thus switching their activity from substrates to 
non-transportable inhibitors. Interestingly, Hutsell and colleagues (Hutsell et al., 2016) 
found that both enantiomers of 4-methylcathinone (nor-mephedrone), acted as fully 
efficacious releasers at SERT in rat brain synaptosomes. This discrepancy may be 
explained by the fact that we used non-neuronal HEK293 cells as the expression system 
or differences between the human and rat isoforms of SERT. 
Binding of racemic mephedrone to α1A, α2A, 5-HT2A and 5-HT2C receptors has been 
reported (Luethi et al., 2018a; Simmler et al., 2013) and Philogene-Khalid and colleagues 
observed that S-mephedrone bound to 5-HT2A and 5-HT2C receptors without agonist 
activity (Philogene-Khalid et al., 2017a). 
We found that S-nor-mephedrone bound to α1A and 5-HT2A receptors and mouse and rat 
TAAR1, albeit with moderate affinity towards 5-HT2A. Agonistic activity at α1A receptors 
is implicated in stimulant-induced behaviours, such as locomotor activity (Schmidt and 
Weinshenker, 2014). For instance, the α1- and β-adrenergic receptor antagonist 
carvedilol reduced cardiostimulant and hyperthermic effects of MDMA in humans, but 
had no effect on subjective effects of the drug (Hysek et al., 2012). The same findings 
regarding carvedilol on mephedrone-induced hyperthermia were reported in rats (Zona 
et al., 2016).  Activation of 5-HT2A-receptors has previously been demonstrated for 
mephedrone (Luethi et al., 2018a) and hallucinogens (Rickli et al., 2016). This effect on 
5-HT2A receptors may partially contribute to hallucinogenic effects (Kraehenmann et al., 
2017; Nichols, 2016) associated with mephedrone (Kasick et al., 2012; Schifano et al., 
2011). Binding to TAAR1 exerts auto-inhibitory effects on monoamine releasing 
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neurons (Revel et al., 2011; Revel et al., 2012), which has been linked to neuroprotective 
effects (Di Cara et al., 2011; Lindemann et al., 2008; Revel et al., 2012). Interestingly, 
binding to rat TAAR1 has been reported for MDMA and mephedrone, with MDMA 
displaying higher affinities than mephedrone (Simmler et al., 2013). However, in 
contrast to MDMA, systemic administration of mephedrone did not deplete the 5-HT 
content in striatum and cortex (Baumann et al., 2012). This observation may be 
explained by different activities of both drugs at the vesicular monoamine transporter 2 
(Cozzi et al., 1999; Pifl et al., 2015). However, this finding also indicates that the exact 
role of TAAR1 in psychostimulant action remains unclear (Sitte and Freissmuth, 2015). 
(1S,2S)-dihydro-mephedrone bound to mouse TAAR1, but not to rat TAAR1.  In contrast, 
(1R,2R)-, (1R,2S)- and (1S,2R)-dihydro-mephedrone bound to rat TAAR1 but not to 
mouse TAAR1. (1S,2S)- and (1R,2S)-dihydro-mephedrone also bound to 5-HT2A- 
receptors and the latter was also found to bind to α2A receptors. Overall, the binding 
data suggest that some of the effects of mephedrone may be shaped – at least in part – 
by the activities of the metabolites at a subset of monoamine receptors.  
In addition to our own in vitro studies, we performed a pilot chiral analysis of a urine 
sample obtained from a human mephedrone user (Figure 5). 4-OH-mephedrone was 
found to be problematic in our assays based on the partial racemization of S- and R- 
enantiomers under assay conditions, consequently affecting calibration curves and 
compound determination in the analysis. Given the limited stability of this metabolite 
and its lower abundance in the urine sample compared to nor-mephedrone, we 
refrained from drawing further conclusions for this metabolite. 
In the case of nor-mephedrone we found that the S- enantiomer is almost 2 times more 
abundant in the human urine sample compared to its R- counterpart; hence, nor-
mephedrone is predominantly excreted in its S-enantiomeric form. This novel finding is 
in excellent agreement with a recent report (Castrignano et al., 2017). Previously, we 
found that systemically administered nor-mephedrone exerts profound effects on 
extracellular serotonin, whereas the effects were less pronounced for dopamine (Mayer 
et al., 2016). According to drug user reports, the subjective effects of mephedrone 
resemble those of MDMA, which markedly affects the serotonergic system (Green et al., 
2014; Schifano et al., 2011). Given the pharmacological profile of mephedrone, i.e. no 
selectivity for SERT (Baumann et al., 2012), it is tempting to speculate that some of the 
subjective effects are linked to S-nor-mephedrone. This interpretation is bolstered by 
the fact that R-mephedrone appears to be the predominant stereoisomer in human 
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samples and waste water (Castrignano et al., 2017). R-mephedrone shows greater 
selectivity for DAT over SERT than S-mephedrone. In line with this finding, only R-
mephedrone induced conditioned place preference (CPP). Furthermore, although both 
enantiomers facilitated intracranial self-stimulation (ICSS), R-mephedrone did so to a 
greater extent (Gregg et al., 2015). ICSS and CPP positively correlate with the rewarding 
effects of psychostimulants, which appear to be defined by the relative DAT/SERT 
selectivity of drugs (Roberts et al., 1999). Considering the higher DAT/SERT ratio of R-
mephedrone and its relative abundance in humans when compared to S-mephedrone, 
this feature provides a potential explanation for the re-dosing of mephedrone within 
sessions (Jones et al., 2016). The pharmacological profiles of R-mephedrone and S-
mephedrone led Philogene-Khalid and colleagues to conclude that the rewarding effects 
of mephedrone are primarily due to the actions of R-mephedrone (Philogene-Khalid et 
al., 2017a). The same authors found that S-mephedrone reduces anxiety and depression-
like effects in rats that were withdrawn from cocaine or MDPV. Possibly, due to the 
increased SERT/DAT ratio of S-mephedrone, administration of this drug adequately 
compensates for deficits in extracellular 5-HT, which are associated with cocaine 
withdrawal (Parsons et al., 1995, 1996). The increased SERT selectivity of S-nor-
mephedrone may contribute to the entactogenic effects of mephedrone (Papaseit et al., 
2017).  
CYP2D6 has been demonstrated to be the main enzyme involved in the metabolism of 
mephedrone (Pedersen et al., 2013). Cytochrome P450 enzymes (CYPs) are abundantly 
expressed in the liver. However, it has been demonstrated that the expression of CYPs is 
not confined to the liver and various CYP isoforms have been detected in the nervous 
system (Ferguson and Tyndale, 2011; Miksys and Tyndale, 2002). CYP2D6 is expressed 
in numerous regions of the human brain (Siegle et al., 2001), including hippocampus 
and striatum (Chinta et al., 2002). Importantly, a recent in vivo study provided evidence 
that CYPs contribute to metabolic processes in the brain (Bromek et al., 2011). Hence,  it 
is tempting to assume that the metabolites can be formed in situ and gain access to 
MATs and monoamine receptors, and shape the overall effects of mephedrone. 
In addition, hepatically formed nor-mephedrone crosses the blood brain barrier, as 
evidenced by its effects on extracellular 5-HT and dopamine in the nucleus accumbens 
upon systemic administration. This might be attributed to its distribution coefficient 
(logD =1.29) (Mayer et al., 2016) as the lipid solubility and size of a substance correlates 
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with its likelihood to enter the brain (van Bree et al., 1988; Waterhouse, 2003) or 
transport processes that have yet to be determined.  
The ability to induce reverse-transport via SERT is essential to the action of MDMA, 
since most of the subjective effects of MDMA were attenuated by co-administration of 
the SERT-inhibitor citalopram (Liechti et al., 2000). This observation further supports 
the hypothesis that S-nor-mephedrone contributes to the action of mephedrone as R-
nor-mephedrone failed to induce release via human SERT. Aside from the effects at 
SERT, stereoselectivity at NET may also affect the pharmacology of mephedrone. 
Administration of the NET-inhibitor reboxetine not only reduced the effects of MDMA on 
heart rate and blood pressure, but also attenuated “drug-liking” and “good drug-effects” 
(Hysek et al., 2011). Olesti et al. (Olesti et al., 2017) recently published a study on the 
pharmacokinetics of mephedrone and its metabolites in human plasma and urine. In 
addition, this study quantified mephedrone and a subset of metabolites in rat prefrontal 
cortex after systemic administration of the parental substance.  
4’carboxy-mephedrone (COOH-mephedrone, which is derived from 4-OH-mephedrone) 
and nor-mephedrone were the most abundant metabolites in human plasma with AUC0-
8h levels of 113% and 46%, respectively, of those of mephedrone after ingestion of 150 
mg of mephedrone (n=6 individuals). Other minor metabolites detected were N-
succinyl-nor-mephedrone (SUCC-mephedrone) (4%) and dihydro-mephedrone (11%). 
The half-life of mephedrone was 2.2 h, compared to 4.5 h (nor-mephedrone), 8.2 h 
(SUCC-mephedrone) 5.7 h (DIHYDRO-mephedrone) and 1.9 h (COHH-mephedrone). 
Moreover, 1h after administration of mephedrone (30 mg/kg; i.p.), the concentration of 
nor-mephedrone in rat prefrontal cortex exceeded the concentration of the parental 
drug by 100%, with COOH-mephedrone and SUCC-mephedrone being detectable in 
small amounts. In the same study, the authors observed Cmax values of 179 ± 29.3 and 
54.4 ± 4.9 (ng/mL, ± SEM) for mephedrone and nor-mephedrone, respectively. 
Considering the moderate dose (150 mg) used in this study, the brain concentrations 
can be expected to be in the low micromolar range after the use of moderate to high 
doses. These findings strengthen the hypothesis that the effects of mephedrone may be 
partially shaped by its metabolites, with an emphasis on nor-mephedrone. 
The limitations of this study are that we did not test conjugated metabolites for their 
activities at monoamine receptors and transporters and that limited information is 
available on the abundance of the metabolites in human brain. 
 20
Hence, further studies are warranted to unravel the pharmacokinetics of the metabolites 
in a time-resolved and stereospecific manner to clarify the overall contribution of the 
metabolites to the effects of mephedrone on neurochemistry and behavior.  
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Table 2: Effect of test drugs on monoamine transporter mediated uptake. 
IC50 (µM) (95 % CI in brackets) 
 DAT NET SERT NET/DAT 
ratio 
DAT/SERT 
ratio 
S-nor-
mephedrone 
 
8.72 
(5.9 to 12.87) 
3.84 
(3.16 to 4.66) 
10.88 
(6.33 to 18.7) 
2.27 1.25 
R-nor-
mephedrone 
 
9.44 
(6.51 to 13.68) 
4.54 
(3.44 to 5.99) 
200.0 
(106.8 to 374.6) 
2,08 21.19 
S-4-OH-
mephedrone 
 
2.63 
(1.98 to 3.49) 
9.53 
(7.49 to 12.14) 
32.05 
(24.39 to 42.13) 
0.28 12.19 
 
R-4-OH-
mephedrone 
 
5.64 
(3.68 to 8.64) 
 
18.04 
(11.76 to 27.67) 
625.4 
(478 to 818.3) 
0.31 110.89 
1S,2R Dihydro-
mephedrone 
 
12.67 
(10.41 to 
15.41) 
22.66 
(18.62 to 27.57) 
65.55 
(40.15 to 107) 
0.56 5.17 
1R,2S Dihydro-
mephedrone 
 
21.11 
(17.21 to 
25.88) 
38.99 
(33.45 to 45.44) 
32.21 
(26.72 to 38.84) 
0.54 1.53 
1R,2R Dihydro-
mephedrone 
 
14.12 
(9.43 to 21.15) 
39.05 
(27.12 to 56.21) 
302.3 
(228.4 to 400.1) 
0.36 21.41 
1S,2S Dihydro-
mephedrone 
 
12.89 
(10.12 to 
16.44) 
47.09 
(27.83 to 79.67) 
248.2 
(220.8 to 279) 
0.27 19.26 
Data are shown as the mean (95% CI in parenthesis), obtained from non-linear 
regression fits as shown in Figure 2. NET/DAT ratio = 1/NET IC50 divided by 1/DAT IC50. 
High value indicates greater NET-selectivity. DAT/SERT ratio = 1/DAT IC50 divided by 
1/SERT IC50. High value indicates greater DAT selectivity. 
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Table 3: Monoamine receptor binding profiles. Binding profiles were obtained as 
described in “materials and methods”. Ki and EC50 values (µM) are given as mean and SD 
from 3 independent measurements. 
 
 
 Human 
TAAR1 
Rat 
TAAR1 
Mouse 
TAAR1 
5HT1A 5HT2A 5HT2B 5HT2C α1A α2A 
 EC50 ± 
SD 
[µM] 
Ki ± SD 
[µM] 
Ki ± SD 
[µM] 
Ki ± 
SD 
[µM] 
Ki ± SD 
[µM] 
EC50 ± 
SD 
[µM] 
Ki ± 
SD 
[µM] 
Ki ± 
SD 
[µM] 
Ki ± SD 
[µM] 
S-nor-
mephedron
e 
>30 0.5873 ± 
0.02 
0.725 ± 
0.026 
> 17 7.41 
±0.305 
>10 >5 1.33 
±0.051 
>4.6 
R-nor-
mephedron
e 
n.d. >5.19 >4.36 >17.5
9 
>12.98 >10 >5.07 >2.24 >4.68 
S-4-OH-
mephedron
e 
n.d. >5.19 >4.36 >17.5
9 
>12.98 >10 >5.07 >2.24 >4.68 
R-4-OH-
mephedron
e 
n.d. >5.19 >4.36 >17.5
9 
>12.98 >10 >5.07 >2.24 >4.68 
(1R, 2R)-
dihydro-
mephedron
e 
n.d. 3.71 
±0.53 
>4.36 >17.5
9 
>12.98 >10 >5.07 >2.24 >4.68 
(1S,2S)-
dihydro-
mephedron
e 
n.d. >5.19 3.85 
±0.39 
>17.5
9 
6.665 
±2.36 
>10 >5.07 >2.24 >4.68 
(1S,2R)-
dihydro-
mephedron
e 
n.d. 3.568±0.
19 
>4.36 >17.5
9 
>12.98 >10 >5.07 >2.24 >4.68 
(1R,2S)-
dihydro-
mephedron
e 
>30 0.558±0.
049 
>4.36 >17.5
9 
7.476±2.1
26 
>10 >5.07 >2.24 1.846±0.
388 
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Table 4: Monoamine transporter binding profiles. Binding profiles were obtained as 
described in “materials and methods”. Ki values [µM] are given as mean and SD from 3 
independent measurements. 
 DAT NET SERT 
 Ki ± SD [µM] Ki ± SD [µM] Ki ± SD [µM] 
S-nor-mephedrone >8.52 >8.77 >7.42  
R-nor-mephedrone >8.52 >8.77 >7.42  
S-4-OH-mephedrone 6.69 ± 1.54 >8.77 >7.42  
R-4-OH-mephedrone >8.52 >8.77 >7.42  
(1R,2R)-dihydro-mephedrone 6.07 ± 0.11 >8.77 >7.42  
(1S,2S)-dihydro-mephedrone >8.52 >8.77 >7.42  
(1S,2R)-dihydro-mephedrone >8.52 >8.77 >7.42  
(1R,2S)-dihydro-mephedrone >8.52 >8.77 >7.42  
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Figure Legends 
 
Figure 1: Chemical structures of the stereoisomers of the phase-1 metabolites of 
mephedrone. 
 
Figure 2: Effects of the stereoisomers of nor-, 4-OH- and dihydro-mephedrone on 
transporter-mediated uptake into HEK293 cells. Uptake of [3H]MPP+ (DAT and NET 
expressing cells) and [3H]5-HT (SERT expressing cells) was inhibited with increasing 
concentrations of the indicated test drugs. Data are shown as the mean and SEM 
obtained from 5 individual experiments, performed in triplicate. 
 
Figure 3: S- and R-nor-mephedrone induced reverse transport via human SERT. 
HEK293 cells stably expressing hSERT were preloaded with tritiated 5-HT and 
superfused with buffer. After the collection of three 2-minute fractions, the test drugs 
were added at the indicated concentrations for five 2-minute fractions. (A) and (C) 
depict the effects of increasing concentrations of test drugs on the fractional release of 
[3H]5-HT. (B) and (D) show the concentration response curves generated in (A) and (C). 
The Averaged efflux rate was defined as the mean of the last three rates (i.e. t=8 to 14 
min) minus the mean of the first three rates (i.e. basal release; i.e. t=0 to 4 min). All data 
are mean and SEM. Φ, #, *, ∧ denote signi`icant differences versus the time-matched 
control (0 µM) for 100, 30, 10 and 3 µM of test drug, respectively (P < 0.05, 
Bonferroni’s). Numbers in parenthesis indicate independent observations performed in 
duplicate as described in materials and methods. S-nor-mephedrone: 0 µM (9), 1 µM 
(10), 3 µM (10), 10 µM (8), 30 µM (10), 100 µM (10). R-nor-mephedrone: 0 µM (5), 1 µM 
(6), 3 µM (7), 10 µM (11), 30 µM (8), 100 µM (7).  
 
Figure 4: S- and R-4-OH-mephedrone induced reverse transport via human SERT. 
The experiment was performed as described in materials and methods and Figure 2. (A) 
and (C) depict the effects of increasing concentrations of test drugs on the fractional 
release of [3H]5-HT. (B) and (D) show the concentration response curves generated in 
(A) and (C). The Averaged efflux rate was defined as the mean of the last three rates (i.e. 
t=8 to 14 min) minus the mean of the first three rates (i.e. basal release; i.e. t=0 to 4 
min). All data are mean and SEM. Φ, #, * denote significant differences versus the time-
matched control (0 µM) for 100, 30 and 10 µM of test drug, respectively (P < 0.05, 
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Bonferroni’s). Numbers in parenthesis indicate independent observations performed in 
duplicates as described in materials and methods. S-4-OH-mephedrone: 0 µM (10), 1 µM 
(11), 3 µM (12), 10 µM (12), 30 µM (12), 100 µM (12). R-4-OH-mephedrone: 0 µM (8), 1 
µM (10), 3 µM (10), 10 µM (9), 30 µM (10), 100 µM (10).  
 
Figure 5: Chromatographic separation of derivatized S- and R-nor-mephedrone in 
human urine sample as pilot study. The urine sample was derivatized as described in 
the methods section and then analysed on a tandem-LC-MS/MS tandem system with an 
analytical HPLC column (Kinetex 1.7 μm C18 100 A 150 x 2.1 mm at 40°C using gradient 
conditions (35% acetonitrile to 100% over 26 minutes, followed by isocratic elution for 4 
minutes)). The experiment was repeated twice, derivatizing 250 μL of the urine sample, 
yielding comparable results. 
